Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2006

View Archived Issues

Pentavalent human-bovine vaccine reduces rotavirus gastroenteritis

Suberoylanilide hydroxamic acid active in lymphoma patients

Synbiotics maintain gut environment in severe SIRS patients

Update on biomarkers in breast cancer

Toyama outlicenses Korean rights for T-3811 to Dong-A

Promising preclinical results in Duchenne muscular dystrophy at VASTox

GemVax and Ulleval University Hospital collaborate on translational research

New subcutaneous formulation of Genasense investigated

Migenix profiles pipeline progress

Clinical candidate selected from Array BioPharma and AstraZeneca collaboration

Eurand inlicenses novel analgesic compounds from Italian universities

Can-Fite BioPharma signs CRADA with NIH for A3 adenosine receptor agonists

Posiphen completes first phase I study for Alzheimer's disease progression

New phase I study investigates PR-104 to treat hypoxic tumors

Curis updates phase I basal cell carcinoma study

Pfizer updates Canadian safety information for Macugen

New pegylated wortmannin conjugates demonstrate antitumor activity

LAB CGRP, safe with no serious adverse events in phase I study

Japanese approval for Plavix

Approvable letter for Yaz

GW-3965 protects against endotoxic liver injury and dysfunction

Novel agents for treating endocrine-related disorders disclosed in recent patents

Recent Vertex patent reports new agents for cystic fibrosis

Antiarrhythmic agents emerge from AstraZeneca R&D

Erectile dysfunction medications may be associated with increased risk of optic nerve damage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...